BRAINSTORM CELL THERAPEUTICS INC.
BCLI · OTCMCIK 1137883fmd_1GDRGPG4R8H4TWYC141RHSKC7TManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Sep 23, 2000 to Jun 30, 2026, 75 periods
Latest annual · FY2025
Millions- Operating income
- (10)
- Net income
- (10)
Latest quarter · Q2 FY2026
Millions- Operating income
- (4)
- Net income
- (4)
Key stats
Open AnalysisCompound annual growth
- Net income, 5 yearsFY2020 to FY2025
- n/m
BRAINSTORM CELL THERAPEUTICS INC. (BCLI) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Operating income | -$10 million | -$11.7 million | 10-K 2026-03-31 · proof | |
| Net income | -$10.3 million | -$11.6 million | 10-K 2026-03-31 · proof | |
| Cash from operating activities | -$7 million | -$9.1 million | 10-K 2026-03-31 · proof | |
| Total assets | $1 million | $1.8 million | -44.2% | 10-K 2026-03-31 · proof |
| Total liabilities | $11 million | $9.6 million | +14.7% | 10-K 2026-03-31 · proof |
| Cash and cash equivalents | $29,000 | $187,000 | -84.5% | 10-K 2026-03-31 · proof |
- What was BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s operating income in fiscal 2025?
- BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported operating income of -$10 million for fiscal 2025 (the year ended Dec 31, 2025), against -$11.7 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s net income in fiscal 2025?
- BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported net income of -$10.3 million for fiscal 2025 (the year ended Dec 31, 2025), against -$11.6 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What was BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s cash from operating activities in fiscal 2025?
- BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported cash from operating activities of -$7 million for fiscal 2025 (the year ended Dec 31, 2025), against -$9.1 million the year before. Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s total assets?
- As of Dec 31, 2025, BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported total assets of $1 million, against $1.8 million a year earlier (-44.2%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s total liabilities?
- As of Dec 31, 2025, BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported total liabilities of $11 million, against $9.6 million a year earlier (+14.7%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
- What are BRAINSTORM CELL THERAPEUTICS INC. (BCLI)'s cash and cash equivalents?
- As of Dec 31, 2025, BRAINSTORM CELL THERAPEUTICS INC. (BCLI) reported cash and cash equivalents of $29,000, against $187,000 a year earlier (-84.5%). Source: the 10-K filed with the SEC on Mar 31, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:BCLI&period_type=annual&limit=5"Information only, not investment advice.